Indication
high risk of recurrence
2 clinical trials
2 products
Clinical trial
Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2024-12-01
Product
LenvatinibClinical trial
A Randomized Multicenter Phase III Trial Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)Status: Completed, Estimated PCD: 2023-12-01
Product
Imatinib